Hepatitis D

Hepatitis D is a specific type of liver inflammation caused by a particular virus called the Hepatitis D virus. This virus can only infect people who already have Hepatitis B. It's like a 'helper' virus that needs Hepatitis B to work. It spreads through things like sharing needles or blood, or sometimes through close contact. It can happen when someone gets both Hepatitis B and D at the same time, or later when they have Hepatitis B.

Condition

What people with Hepatitis D report

Every report comes from a Lived member, sent anonymously.

Have you tried Hepcludex (Bulevirtide) for Hepatitis D?

NameHow it went

About Hepatitis D

What It Is

Hepatitis D is inflammation of the liver caused by the hepatitis D virus, also called hepatitis delta. It is an unusual virus because it cannot copy itself on its own: it needs the hepatitis B virus to do so. As a result, hepatitis D only occurs in people who also have hepatitis B. The two viruses can be caught at the same time (coinfection), or hepatitis D can be added to a hepatitis B infection someone already has (superinfection). The difference matters. After a coinfection, most people recover fully, and long-term hepatitis D is uncommon. A superinfection usually becomes long-lasting and makes existing liver disease worse. Long-term (chronic) hepatitis D is considered the most severe form of chronic viral hepatitis. Compared with hepatitis B alone, it tends to scar the liver faster, leading to cirrhosis (advanced scarring) and a higher chance of liver cancer. Many people feel well for years, which is why testing matters more than symptoms.

Causes & Risk Factors

Hepatitis D spreads the same way hepatitis B does: through contact with infected blood and other body fluids. That includes sharing needles or other drug equipment, sex with an infected partner and, less often, from a mother to her baby around birth. In some regions it also spreads within households. The main risk factor is having hepatitis B. Among people with hepatitis B, hepatitis D is more common in those who inject drugs, people living with hepatitis C or HIV, people on dialysis, and people from or with family ties to regions where it is common, including Mongolia, Moldova, parts of West and Central Africa, Central Asia, the Middle East and the Amazon Basin. A severe Amazon form of the infection has been known locally as Labrea fever. Because hepatitis D cannot exist without hepatitis B, the hepatitis B vaccine also prevents hepatitis D. The vaccine does not help someone who already has hepatitis B; for them, prevention means avoiding further blood exposure, such as not sharing needles, razors or toothbrushes.

How It's Diagnosed

Hepatitis D is diagnosed with blood tests, usually in two steps. The first is an antibody test, which shows whether a person has ever been infected. If it is positive, a second test looks for the virus's genetic material (its RNA) in the blood. A positive result on this second test means the infection is active; a negative one after a positive antibody test usually means a past infection that has cleared. The tests are only relevant for people who have hepatitis B, shown by a positive hepatitis B surface antigen (HBsAg) test. Guidance on whom to test differs: some liver societies recommend testing everyone with hepatitis B at least once, while US guidance has focused on people with risk factors. Testing in the US is uncommon, so many people with hepatitis D do not know they have it. If you have hepatitis B and have never been tested, it is reasonable to ask. Once the infection is confirmed, the care team assesses how much scarring the liver has. This is often done with liver blood tests and a painless ultrasound-based scan that measures liver stiffness (such as FibroScan), and sometimes with a liver biopsy. The degree of scarring shapes treatment choices and how often follow-up is needed.

Treatment Options

Treatment aims to suppress the hepatitis D virus, calm liver inflammation and slow the progression toward cirrhosis and liver cancer. It is usually managed by a liver specialist (hepatologist). The standard hepatitis B antiviral pills, such as tenofovir or entecavir, control hepatitis B but do not work against hepatitis D. Many people still take them for the hepatitis B infection. Bulevirtide (Hepcludex) is the first medicine approved in the US specifically for chronic hepatitis D. It blocks the virus from entering liver cells and is given as a daily injection under the skin, which people learn to do at home. It is approved for adults without cirrhosis or with cirrhosis that has not caused serious complications. In the main trial, about half of people met the combined goal of a large drop in virus levels plus normal liver enzyme tests after a year, and the share with no detectable virus kept rising over three years. The approval is based on those lab results; whether it reduces cirrhosis, liver cancer or deaths is still being studied. Common side effects are injection site reactions, headache, tiredness and itching. Treatment usually continues as long as it is working, and stopping it can cause a severe flare of hepatitis D and B, so any decision to stop is made with the specialist and followed by close monitoring for at least six months. Peginterferon alfa, a weekly injection that boosts the immune response, has been used for years outside its formal approval. Only about one in five people clear the virus for the long term, relapse is common, and side effects often require dose changes. Other medicines are being tested in clinical trials. For people whose liver is failing or who develop certain liver cancers, a liver transplant can be an option.

What to Expect

Chronic hepatitis D is usually a long-term condition that needs regular follow-up rather than a single course of treatment. The pace varies: some people stay stable for many years, while others develop cirrhosis within a few years of infection. Treatment can lower virus levels and liver inflammation, but a complete cure, meaning loss of both viruses, is uncommon with current options. Routine care typically includes blood tests every few months to check liver function and virus levels, periodic liver stiffness scans, and regular liver ultrasound to look for early liver cancer when it is most treatable. People on daily injections fit them into their routine and keep their supplies on hand so doses are not missed. Protecting the liver makes a real difference. Avoiding alcohol and checking with a clinician before starting new medicines or supplements are common recommendations. Household members and sexual partners should be tested for hepatitis B and vaccinated if they are not immune, which also protects them from hepatitis D.

When to Seek Help

If you have hepatitis B and have never been tested for hepatitis D, ask for the test at your next visit. People with hepatitis D should keep regular appointments with their liver specialist even when they feel well. Contact your care team promptly if you notice yellowing of the skin or eyes, dark urine, pale stools, or new swelling of the belly or legs, especially after stopping or missing treatment. Vomiting blood or passing black, tarry stools can signal bleeding from enlarged veins in a scarred liver and needs emergency care right away.

Questions to Ask Your Doctor

  1. 1.Does my hepatitis D test show an active infection or a past one, and how much scarring does my liver have?
  2. 2.Am I a candidate for bulevirtide or another treatment, and how will we know whether it is working?
  3. 3.How often should I have blood tests, liver scans and liver cancer screening?
  4. 4.What should I do if I need to stop treatment or miss doses?
  5. 5.Who in my household should be tested or vaccinated for hepatitis B?

Last reviewed • Oct 2026

Educational content, not medical advice.